Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

Background Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the po...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Wang, Hao Wu, Jing Sun, Xiao Li, Yongqian Shu, Xiaofeng Wu, Guoqiang Wang, Huajun Li, Xiaofeng Chen, Yanhong Gu, Yang Shao, Qianwen Shao, Feipeng Zhu, Xiaofeng Qian, Jun Hu, Fengjiao Zhao, Weidong Mao, Gaohua Han, Changxian Li, Yongxiang Xia, Poshita Kumari Seesaha, Dongqin Zhu, Junling Zhang, Xuehao Wang, Xiangcheng Li
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001240.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001240.full

Similar Items